Initial multicentre experience of

To evaluate the safety and short-term oncological outcomes ofBetween February 2014 and April 2016, 35 patients across two centres underwent RASND forA total of 58 lesions suspicious for lymph node metastases (LNM) in 35 patients were detected onAlthough RASND appears safe and feasible, less than half of our cohort had a treatment response, and less than a quarter experienced BCR-free survival at 12-month median follow-up.